Prognostic significance of percentage of bronchioloalveolar pattern in adenocarcinomas of the lung

Annals of Diagnostic Pathology

Volumn 5, Issue 5, 2001, Pages 274-284

  Castro, Claudia Y ^a   Coffey, Dona M ^a,c   Medeiros, L Jeffrey ^a,b   Cagle, Philip T ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Bronchioloalveolar; cyclin D1; cyclin E; Growth pattern; Immunohistochemistry; p16; p53; Retinoblastoma

Indexed keywords

CYCLIN D1; CYCLIN E; PARAFFIN; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; CANCER CLASSIFICATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PARENCHYMA; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; TISSUE SECTION; TUMOR GROWTH;

EID: 0034798931     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1053/adpa.2001.27915     Document Type: Article

References (52)

1. Lung cancer
2. Bronchioloalveolar carcinoma: The significance of two histopathologic types
3. Differentiating bronchioloalveolar carcinoma from adenocarcinoma
4. Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung
5. Recurrence survival following resection of bronchioloalveolar carcinoma of the lung-The Lung Cancer Study Group experience
6. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicoathologic features
7. Bronchoalveolar carcinoma: Factors affecting survival
8. Morphologic immunocytochemical studies of bronchioloalveolar carcinoma at Duke University Medical Center, 1968-1986
9. Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma
10. Small adenocarcinoma of the lung: Histologic characteristics and prognosis
11. Bronchoalveolar carcinoma: Clinical, radiologic, pathologic factors and survival
12. Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung
13. Histopathologic features of mixed patterns of adenocarcinomas with bronchioloalveolar component. Clinical significance in 115 tumors
14. Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioloalveolar cell carcinoma
15. Alveolar cell carcinoma of the lung: A retrospective analysis of 205 patients
16. Bronchoalveolar cell carcinoma of the lung
17. Bronchoalveolar carcinoma: Histopathologic study of evolution in a series of 105 surgically treated patients
18. Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3)
19. Cyclins and breast cancer
20. Deregulated cyclin E induces chromosome instability
21. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas
22. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes
23. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected nonsmall cell lung cancer. A preliminary report of LCSG 871
24. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection
25. Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 p53 in 150 patients
26. Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor
27. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival
28. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer
29. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer
30. The prognosticvalue of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer
31. Altered retinoblastomaand p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis
32. Altered retinoblastoma protein expression in non-small cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis
33. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction
34. p53 status is associated with a favorable prognosis in patients with stage I-IIIa non-small cell lung cancer
35. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: Relationship with p53 and MDM2 protein expression
36. Do molecular markers predict survival in non-small-cell lung cancer?
37. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosit, and other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers
38. Prognostic significance of different biomarkers in non-small cell lung cancer
39. Clinical significance of p53 in non-small-cell lung cancer
40. Mutations of cell cycle regulators. Bioogical and clinical implications for human neoplasia
41. Inactivation of Rb gene and pRR function in lung cancer
42. Rb and p16INK4a expression in resected non-small cell lung tumors
43. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study
44. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers
45. A study on p16, pRb, cdk4 and cyclin D1 expression in non-small cell lung cancers
46. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer
47. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer
48. G1 control gene status is frequently altered in resectable non-small cell lung cancer
49. Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen
50. Prognostic value of the immunohistochemical detection of p16INK4 expression in non-small cell lung carcinoma
51. Clinical implications of cyclins, cyclin-dependent kinases. Prognostic value of p16 expression in lung adenocarcinoma